About Palbociclib API
Therapeutic Category Oncology

CAS Number
571190-30-2
API Technology
Synthetic
Dose Form
Capsule/ Tablet
Dr Reddy's Development Status
Available
Available Regulatory Filing
Brazil DMF, USDMF, Singapore DMF, Australia DMF, Canada DMF, Taiwan DMF
Mechanism of Action
It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Indication
IBRANCE is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
- An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
- Fulvestrant in women with disease progression following endocrine therapy.
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
FAQs
What is Palbociclib API used for?
Treats HR-positive, HER2-negative advanced or metastatic breast cancer.
What is the dosage form and strength currently available for Palbociclib?
Available as oral tablets: 75 mg, 100 mg, 125 mg.
How do you store Palbociclib API?
Store at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F).